ALT vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALT vs LLY: Head-to-Head Comparison
This page compares Altimmune, Inc. (ALT) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.